Could Aldeyra Therapeutics Inc (NASDAQ:ALDX) Go Down After Its Newest Short Interest Report?

June 17, 2018 - By Marguerite Chambers

Investors sentiment increased to 3 in Q1 2018. Its up 1.38, from 1.62 in 2017Q4. It is positive, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 6 reduced holdings. 10 funds opened positions while 17 raised stakes. 10.28 million shares or 3.03% more from 9.98 million shares in 2017Q4 were reported.
Savings Bank Of New York Mellon Corporation holds 0% or 20,791 shares in its portfolio. Northern Trust reported 48,151 shares. National Bank Of America Corporation De owns 4,615 shares for 0% of their portfolio. Acadian Asset Management Ltd Company holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 7,918 shares. Renaissance Techs Ltd Liability reported 30,600 shares. Weiss Multi reported 47,400 shares. Royal Comml Bank Of Canada holds 0% or 40 shares in its portfolio. Jefferies Ltd Liability Corporation, a New York-based fund reported 11,900 shares. Perceptive Advsr Ltd Liability Corporation accumulated 3.09 million shares. Stifel owns 10,367 shares or 0% of their US portfolio. Prelude Mgmt Lc has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Japan-based Hikari Power Limited has invested 0.1% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Woodstock holds 0.1% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 67,759 shares. Wells Fargo Mn accumulated 0% or 14,531 shares. Fmr Llc accumulated 1.61 million shares or 0% of the stock.

The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) registered a decrease of 19.87% in short interest. ALDX’s total short interest was 307,300 shares in June as published by FINRA. Its down 19.87% from 383,500 shares, reported previously. With 119,700 shares average volume, it will take short sellers 3 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Inc’s float is 8.49%.

The stock increased 2.31% or $0.2 during the last trading session, reaching $8.85. About 116,129 shares traded or 31.29% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 82.11% since June 17, 2017 and is uptrending. It has outperformed by 69.54% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $177.97 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 3 analyst reports since January 26, 2018 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 15. Cantor Fitzgerald maintained the shares of ALDX in report on Thursday, March 29 with “Buy” rating.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.